ACRS

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

Nothing here yet

News

• Aclaris Therapeutics received Fast Track designation for modzatinib (ATI-2138) for moderate to severe lichen planusAug 7, 2026
• Aclaris reported positive full topline Phase 1a results for ATI-052 and selected lichen planus as the lead indication for ATI-2138Apr 28, 2026
• Aclaris' ITK/JAK3 inhibitor ATI-2138 showed rapid hair regrowth in alopecia modelJan 27, 2026
• Aclaris Therapeutics initiated Phase 1b proof-of-concept trial with ATI-052 in atopic dermatitisJan 12, 2026
• Aclaris Therapeutics reports positive interim Phase 1a results for ATI-052 anti‑TSLP/IL‑4Rα bispecific antibody supporting faster clinical developmentJan 6, 2026